Current Pharmaceutical Design
Title:Editorial [Hot Topics Anxiety Disorders, Advances in Neurobiology and Neuropharmacology (Executive Guest Editor: Dirk Wedekind)]
Volume: 18 Issue: 35
Author(s): Dirk Wedekind
Affiliation:
Export Options
About this article
Cite this article as:
Wedekind Dirk, Editorial [Hot Topics Anxiety Disorders, Advances in Neurobiology and Neuropharmacology (Executive Guest Editor: Dirk Wedekind)], Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530736
DOI https://dx.doi.org/10.2174/138161212803530736 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
26
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression
CNS & Neurological Disorders - Drug Targets Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Current Aging Science Cysteinet Dysregulation in Muscular Dystrophies: A Pathogenic Network Susceptible to Therapy
Current Medicinal Chemistry Recent Developments in Deception Research
Current Psychiatry Reviews P2X1 and P2X2 Receptors in the Central Nervous System as Possible Drug Targets
CNS & Neurological Disorders - Drug Targets The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Current Aging Science A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future Directions
Current Pharmaceutical Design Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Characteristics of Insomniacs Having Sleep State Misperception
Neuroscience and Biomedical Engineering (Discontinued) Mechanical Methods for Dry Particle Coating Processes and Their Applications in Drug Delivery and Development
Recent Patents on Drug Delivery & Formulation Mitochondrial Diseases in Childhood
Current Molecular Medicine New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry Fibromyalgia Syndrome: Which Antidepressant Drug Should We Choose
Current Pharmaceutical Design Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Investigation of Diagnostic Proteins by 2D Electrophoresis in Major Depression Model Induced by Forced Swim Test in Rats
Protein & Peptide Letters Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science